04:53 PM EST, 11/10/2025 (MT Newswires) -- Profound Medical ( PROF ) was at last look up 3.8% in the US after-hours trade Monday after saying it has regained exclusive Canadian distribution rights for the TULSA-PRO system from Knight Therapeutics ( KHTRF ) .

The TULSA Procedure, performed using the TULSA-PRO system, is used by physicians to ablate prostate tissue in men with prostate cancer or benign prostatic hyperplasia, also known as an enlarged prostate, according to the statement.

Profound had previously granted Knight exclusive Canadian distribution rights under a 2015 agreement. The company has now regained those rights in exchange for a one-time cash payment of C$90,000 (US$64,000) and a 5% royalty on Canadian net sales for 15 years, the company said.

"Moving forward, as the results of the Level I prostate cancer CAPTAIN trial comparing the TULSA Procedure head-to-head with robotic radical prostatectomy are published in 2026 and beyond, we plan to use them to support our applications to the appropriate Canadian Provincial Health Insurance authorities for coverage, Profound Medical ( PROF ) Chief Executive Arun Menawat said.

PRN was unchanged in Canada trade today.